Itamar Medical Ltd. provided revenue guidance for the third quarter and full year of 2020. Total revenue for the third quarter of 2020 is expected to be $10.7 million to $11.0 million, an increase of 32% to 36% compared to $8.1 million in the same quarter in 2019. U.S. WatchPAT revenue for the third quarter of 2020 is expected to be $8.6 million to $8.9 million, an increase of 51% to 56% compared to $5.7 million in the same quarter in 2019. On April 13, 2020, the company withdrew its full year 2020 revenue guidance due to the then prevailing global market environment and uncertainties resulting from the COVID-19 outbreak. The Company is reinstating its full year 2020 revenue guidance to a range of $39.5 million to $40.5 million, reflecting growth of approximately 26% to 29% over full year 2019 revenue of $31.3 million and growth of 30% to 34%, excluding a one-time $1 million sale in 2019 to Kaiser Permanente.